Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gin-Ming Hsu

Physical Medicine & Rehabilitation Denver, CO Medical Doctor

NPI 1265415988 CMS profile 238206

2480 S Downing St Ste 210, Denver, CO 80210

Open in the dashboard

General payments

$7,629

323 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gin-Ming Hsu of Denver, CO is reported in the CMS Open Payments database as having received $7,629 across 323 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,760 29
2024 General $859 31
2023 General $1,066 41
2022 General $1,356 59
2021 General $976 59
2020 General $912 59
2019 General $700 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gin-Ming Hsu
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Gin-Ming Hsu were reported at $1,760. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Gin-Ming Hsu Physical Medicine & Rehabilitation median Middle half National median
2019 $700 $133 $45–$390 $163
2020 $912 $88 $29–$272 $114
2021 $976 $116 $33–$360 $132
2022 $1,356 $123 $40–$378 $149
2023 $1,066 $131 $43–$396 $160
2024 $859 $141 $45–$409 $164
2025 $1,760 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SPR Therapeutics, Inc $1,287 7 payments
  2. Collegium Pharmaceutical, Inc. $1,063 81 payments
  3. AbbVie, Inc. $860 29 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $447 31 payments
  5. Allergan Inc. $423 25 payments
  6. Boston Scientific Corporation $404 14 payments
  7. Ipsen Biopharmaceuticals, Inc $362 16 payments
  8. Saluda Medical Americas, Inc. $277 6 payments
  9. Amgen Inc. $265 10 payments
  10. Merz Pharmaceuticals, LLC $228 11 payments
  11. Other $2,015 93 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,462 320 payments
  2. Travel and Lodging $1,088 2 payments
  3. Education $80 1 payment
Products named General payments · program years 2019–2025
  1. SPRINT PNS System $1,287 7 payments
  2. XTAMPZA $862 68 payments
  3. BOTOX Neuroscience $392 5 payments
  4. BOTOX Hyperhydrosis $383 24 payments
  5. DYSPORT $362 16 payments
  6. RELISTOR $309 23 payments
  7. AIMOVIG $304 13 payments
  8. BOTOX Botox Therapeutic $298 14 payments
  9. Evoke $263 5 payments
  10. BELBUCA $200 13 payments
  11. Other $3,228 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

101

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$2,338

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

20.8%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 15 $928
Oxycodone Hcl Generic 21 $624
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 21 $359
Gabapentin Generic 31 $305
Tramadol Hcl Generic 13 $121

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$135,550

Of which drugs: $6,156

Medicare patients

165

Average age 71

Services billed

3,545

94 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 64%
Depression 34%
Chronic kidney disease 33%
Ischemic heart disease 25%
Diabetes 24%
COPD 18%
Heart failure 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml Q9965 Office 37 441 $499
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 38 295 $213
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 16 262 $24

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $162
$162 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $131
$131 — —
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $88
$88 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $34
$34 — —
UBRELVY
  • AbbVie, Inc. $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

323 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record